Ali Abdalla Yasir Osman, Subramaniam Bavani, Nyamathulla Shaik, Shamsuddin Noorasyikin, Arshad Norhafiza M, Mun Kein Seong, Awang Khalijah, Nagoor Noor Hasima
Institute of Biological Sciences (Genetics and Molecular Biology), Faculty of Science, Universiti Malaya, 50603 Kuala Lumpur, Malaysia.
Department of Pharmaceutical Technology, Faculty of Pharmacy, Universiti Malaya, 50603 Kuala Lumpur, Malaysia.
J Trop Med. 2022 Mar 11;2022:5794350. doi: 10.1155/2022/5794350. eCollection 2022.
The ethnopharmacological information gathered over many centuries and the presence of diverse metabolites have made the medicinal plants as the prime source of drugs. Despite the positive attributes of natural products, there are many questions pertaining to their mechanism of actions and molecular targets that impede their development as therapeutic agents. One of the major challenges in cancer research is the toxicity exerted by investigational agents towards the host. An understanding of their molecular targets, underlying mechanisms can reveal their anticancer efficacy, help in optimal therapeutic dose selection, to mitigate their side effects and toxicity towards the host. The purpose of this review is to collate details on natural products that are recently been investigated extensively in the past decade for their anticancer potential. Besides, critical analysis of their molecular targets and underlying mechanisms on multiple cancer cell lines, an in-depth probe of their toxicological screening on rodent models is outlined as well to observe the prevalence of their toxicity towards host. This review can provide valuable insights for researchers in developing methods, strategies during preclinical and clinical evaluation of anticancer candidates.
几个世纪以来收集的民族药理学信息以及多种代谢物的存在，使药用植物成为药物的主要来源。尽管天然产物具有积极特性，但关于它们的作用机制和分子靶点仍存在许多问题，这阻碍了它们作为治疗剂的开发。癌症研究中的一个主要挑战是研究药物对宿主产生的毒性。了解它们的分子靶点和潜在机制可以揭示它们的抗癌功效，有助于选择最佳治疗剂量，减轻它们对宿主的副作用和毒性。本综述的目的是整理过去十年中最近被广泛研究其抗癌潜力的天然产物的详细信息。此外，还概述了对它们在多种癌细胞系上的分子靶点和潜在机制的批判性分析，以及对它们在啮齿动物模型上的毒理学筛选的深入探究，以观察它们对宿主毒性的普遍性。这篇综述可以为研究人员在抗癌候选药物的临床前和临床评估中开发方法和策略提供有价值的见解。
